Homeopathy: Curative, Concurrent and Supportive Cancer Treatment Potential

Oroma Beatrice Nwanodi
{"title":"Homeopathy: Curative, Concurrent and Supportive Cancer Treatment Potential","authors":"Oroma Beatrice Nwanodi","doi":"10.4172/2329-6771.1000194","DOIUrl":null,"url":null,"abstract":"Background: Homeopathy is used by 12 to 24% of European cancer patients, representing 40.4% of patients at European integrative cancer centers. In 2011, a Swiss literature review on homeopathy led to homeopathic treatment coverage in the Swiss national health insurance program. Homeopathy for curative pediatric cancer treatment is limited to 7.4% in the Netherlands, but, 76.5% of German parents will use homeopathy as part of their children’s cancer treatment. The purpose of this paper is to determine what is needed for homeopathy to play a larger role in curative, concurrent, and supportive cancer treatment. \nMethods: PubMed searches in September 2016 and January 2017 were performed with search terms “adverse effects, breast cancer, cancer, cervical cancer, endometrial cancer, homeopathy, ovarian cancer, prevention, treatment”. Curative, concurrent, and supportive homeopathic cancer treatments material was taken from these searches. \nFindings: At least five homeopathic formulations are immunologic adjuvants, activating natural killer cell destruction of cancer and virally infected cells. Ultramolecular Carcinosin, Phytolacca decandra, Conium, Thuja and Klimaktoplan® are appropriate for in vivo breast cancer trials. Lycopodium clavatum 5C and 15C are ready for in vivo cervical cancer trials. Sulphur 30C, may be considered for non-small cell lung adenocarcinoma treatment trials. Conventional cancer treatment associated anxiety, asthenia, depression, dermatitis, folliculitis, hot flushes, insomnia, nausea and vomiting, and stomatitis, respond to numerous homeopathic treatments including hetero-isotherapy. \nConclusion & Significance: In vitro studies and retrospective case series indicate that homeopathy could provide curative cancer treatment for an array of cancers: Breast, cervix, gallbladder, liver, lung, oral, pancreas, periampullary, skin, and stomach. Appropriately designed randomized controlled trials (RCT) based on reproducible homeopathic treatments and clinical protocols, with intent-to-treat analysis will have increased validity. If these RCT have positive outcomes homeopathy will secure a position in curative, concurrent, and supportive cancer treatment.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"16 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6771.1000194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Homeopathy is used by 12 to 24% of European cancer patients, representing 40.4% of patients at European integrative cancer centers. In 2011, a Swiss literature review on homeopathy led to homeopathic treatment coverage in the Swiss national health insurance program. Homeopathy for curative pediatric cancer treatment is limited to 7.4% in the Netherlands, but, 76.5% of German parents will use homeopathy as part of their children’s cancer treatment. The purpose of this paper is to determine what is needed for homeopathy to play a larger role in curative, concurrent, and supportive cancer treatment. Methods: PubMed searches in September 2016 and January 2017 were performed with search terms “adverse effects, breast cancer, cancer, cervical cancer, endometrial cancer, homeopathy, ovarian cancer, prevention, treatment”. Curative, concurrent, and supportive homeopathic cancer treatments material was taken from these searches. Findings: At least five homeopathic formulations are immunologic adjuvants, activating natural killer cell destruction of cancer and virally infected cells. Ultramolecular Carcinosin, Phytolacca decandra, Conium, Thuja and Klimaktoplan® are appropriate for in vivo breast cancer trials. Lycopodium clavatum 5C and 15C are ready for in vivo cervical cancer trials. Sulphur 30C, may be considered for non-small cell lung adenocarcinoma treatment trials. Conventional cancer treatment associated anxiety, asthenia, depression, dermatitis, folliculitis, hot flushes, insomnia, nausea and vomiting, and stomatitis, respond to numerous homeopathic treatments including hetero-isotherapy. Conclusion & Significance: In vitro studies and retrospective case series indicate that homeopathy could provide curative cancer treatment for an array of cancers: Breast, cervix, gallbladder, liver, lung, oral, pancreas, periampullary, skin, and stomach. Appropriately designed randomized controlled trials (RCT) based on reproducible homeopathic treatments and clinical protocols, with intent-to-treat analysis will have increased validity. If these RCT have positive outcomes homeopathy will secure a position in curative, concurrent, and supportive cancer treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
顺势疗法:治疗性、并发性和支持性癌症治疗潜力
背景:顺势疗法被12%至24%的欧洲癌症患者使用,占欧洲综合癌症中心患者的40.4%。2011年,一篇关于顺势疗法的瑞士文献综述将顺势疗法纳入瑞士国家健康保险计划。在荷兰,顺势疗法治疗儿童癌症的比例仅为7.4%,但76.5%的德国父母将顺势疗法作为孩子癌症治疗的一部分。本文的目的是确定顺势疗法在治疗性、并发性和支持性癌症治疗中发挥更大作用所需要的条件。方法:2016年9月和2017年1月在PubMed检索,检索词为“不良反应、乳腺癌、癌症、宫颈癌、子宫内膜癌、顺势疗法、卵巢癌、预防、治疗”。治疗性、并发性和支持性顺势疗法癌症治疗材料取自这些搜索。结果:至少五种顺势疗法制剂是免疫佐剂,激活自然杀伤细胞破坏癌症和病毒感染细胞。ultrammolecular Carcinosin、Phytolacca decandra、Conium、Thuja和Klimaktoplan®适用于乳腺癌体内试验。棒状石蒜5C和15C已准备好在体内进行宫颈癌试验。硫30C,可考虑用于非小细胞肺腺癌治疗试验。传统的癌症治疗相关的焦虑、虚弱、抑郁、皮炎、毛囊炎、潮热、失眠、恶心和呕吐以及口炎,对许多顺势疗法有反应,包括异源等疗法。结论与意义:体外研究和回顾性病例系列表明,顺势疗法可为乳腺癌、宫颈癌、胆囊癌、肝癌、肺癌、口腔癌、胰腺癌、壶腹周围癌、皮肤癌和胃癌等一系列癌症提供根治性治疗。适当设计的随机对照试验(RCT)基于可重复的顺势疗法治疗和临床方案,并进行意向治疗分析,将提高有效性。如果这些随机对照试验有积极的结果,顺势疗法将在治疗性、并发性和支持性癌症治疗中占据一席之地。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Time-restricted Eating to Address Cancer-related Fatigue among Cancer Survivors: A Single-arm Pilot Study. PROGNOSTIC IMPORTANCE OF MOLECULAR GENETIC MARKERS: Ki67, Bcl2, and p53 IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER Role of Vitronectin as a potential Serum Biomarker for Breast Cancer Prognosis Botulinum Toxin Usefulness in the Treatment of Drooling in Childhood Breast cancer risk factors, prevention and patients empowerment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1